Cetrorelix Acetate
Cetrorelix Acetate structure
|
Common Name | Cetrorelix Acetate | ||
|---|---|---|---|---|
| CAS Number | 145672-81-7 | Molecular Weight | 1491.09000 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C72H96ClN17O16 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS08 |
Signal Word | Warning | |
Use of Cetrorelix AcetateCetrorelix Acetate is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM. Sequence: N-acetyl-{2-Naph-Ala}-{Cl-Phe}-{3Py-Ala}-Ser-Tyr-{Cit}-Leu-Arg-Pro-Ala-NH2. |
| Name | cetrorelix acetate |
|---|
| Description | Cetrorelix Acetate is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM. Sequence: N-acetyl-{2-Naph-Ala}-{Cl-Phe}-{3Py-Ala}-Ser-Tyr-{Cit}-Leu-Arg-Pro-Ala-NH2. |
|---|---|
| Related Catalog | |
| Target |
IC50: 1.21 nM GnRH[1]. |
| In Vitro | Cetrorelix Acetate inhibits growth of ES-2 cell line at 1000 ng/ml. Cetrorelix Acetate has comparable antiproliferative effects as GnRH-I agonists indicating that the dichotomy of GnRH-I agonists and antagonists might not apply to the GnRH-I system in cancer cells[2]. |
| References |
| Molecular Formula | C72H96ClN17O16 |
|---|---|
| Molecular Weight | 1491.09000 |
| Exact Mass | 1489.69000 |
| PSA | 532.97000 |
| LogP | 6.02320 |
| Storage condition | -20°C |
|
Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency.
Hum. Reprod. 30(3) , 608-15, (2015) Is ovarian tissue cryopreservation using vitrification followed by in vitro activation (IVA) of dormant follicles a potential approach for infertility treatment of patients with primary ovarian insuff... |
|
|
Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience.
J. Assist. Reprod. Genet. 32(4) , 587-96, (2015) To compare the in-vitro fertilization (IVF) outcomes of cancer patients who underwent oocyte retrieval and embryo/oocyte cryopreservation prior to gonadotoxic therapy to those of age and time-matched ... |
|
|
Sperm morphological normality under high magnification predicts laboratory and clinical outcomes in couples undergoing ICSI.
Hum. Fertil. (Camb.) 18 , 81-6, (2015) The objective of this study was to evaluate whether 'motile sperm organelle morphology examination' (MSOME) is correlated with the outcome of ICSI. A total of 14400 spermatozoa from 72 couples undergo... |